A Phase 3 interventional study of Trifarotene in Acne Vulgaris, sponsored by Galderma R&D. Completed at 9 sites in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2021-12-15.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 3, and was the 5th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2019.
This study's enrollment of 47 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 41st largest by enrollment of the 46 interventional ones that give a count, is the only one that started in 2019, is one of 20 in phase 3, and was the 45th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris
There was no formal hypothesis to be tested. Approximately 50 subjects would be enrolled to evaluate the subject reported outcomes (quality of life and satisfaction survey). The sample size was not based on any formal hypothesis testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants applied Trifarotene 50 μg/g topically once daily in the evening for 24 weeks.
Drug: Trifarotene
Topical Cream
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24
The DLQI was validated 10-item questionnaire for participants aged \>16 years that measured the dermatology-related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). The total DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in C-DLQI (Children's Dermatology Life Quality Index) Score at Week 12 and 24
The C-DLQI are validated 10-item questionnaire for participants aged \<=16 that measured the dermatology related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). Questions were scored as follows: No effect (0-1), Small effect (2-6), Moderate effect (7-12), Very large effect (13-18), Extremely large effect (19-30). The total C-DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 (Extremely large effect) and a minimum of 0 (No effect). A lower score on the C-DLQI indicates increased QOL.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne (CompAQ) Total Score at Week 12, 24
The CompAQ questionnaire is a comprehensive measure of facial and truncal acne's impact on health-related QOL. The 20 questions consisted of 5 domains that assessed a variety of psychosocial and physical impacts of acne: Psychological/Emotional, Social (Judgement from Others), Social Interactions, Treatment Concerns, Physical Symptoms. Each question is assessed with a numeric score between 0 (Never) and 8 (All the time) with a total possible score range of 0 (No effect) -160 (greater adverse impact). The higher the score, the more quality of life is impaired.
Time frame: Baseline, Week 12 and Week 24
Number of Participants With Satisfaction Questionnaire - Treatment Area Face at Week 12 and 24/End of Treatment (ET)
Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.
Time frame: Week 12 and Week 24/End of Treatment (ET)
Number of Participants With Satisfaction Questionnaire - Treatment Area Trunk at Week 12 and 24/ End of Treatment (ET)
Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.
Time frame: Week 12 and Week 24/ET
Change From Baseline in EQ-5D-5L Index Score at Week 12 and 24
EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United States (US) algorithm, with scores ranging from -0.109 (extreme problems) to 1 (no problems). A higher score indicates better health state.
Time frame: Baseline, Week 12 and Week 24
Change From Baseline in EQ-5D-5L VAS at Week 12 and 24
The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 (the worst imaginable health) to 100 (the best imaginable health), with higher scores indicating higher health utility.
Time frame: Baseline, Week 12 and Week 24
Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12 and Week 24
IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24.
Time frame: Baseline, Week 12 and Week 24
Percentage of Participants With Physician's Global Assessment of Truncal Acne Success Rate at Week 12 and 24
The Physician's Global Assessment (PGA) was an instrument to evaluate the truncal acne severity in the shoulders, upper back and upper anterior chest areas. PGA was recorded from components collected on the CRF using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an PGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24. All missing values were imputed by LOCF.
Time frame: Week 12 and 24
Percent Change From Baseline in Facial Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24
Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
Time frame: Baseline, Week 12 and 24
Percent Change From Baseline in Trunk Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24
Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
Time frame: Baseline, Week 12 and Week 24
The study was conducted at United States between 27 March 2019 and 23 December 2019.
| Milestone | Trifarotene |
|---|---|
| Started | 47 |
| Treated | 46 |
| Completed | 33 |
| Not completed | 14 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Other than specified | 3 |
The DLQI was validated 10-item questionnaire for participants aged \>16 years that measured the dermatology-related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). The total DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.
| score on a scale | Trifarotene |
|---|---|
| Week 12 | -1.8 ± 2.97 |
| Week 24 | -0.5 ± 5.85 |
The C-DLQI are validated 10-item questionnaire for participants aged \<=16 that measured the dermatology related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). Questions were scored as follows: No effect (0-1), Small effect (2-6), Moderate effect (7-12), Very large effect (13-18), Extremely large effect (19-30). The total C-DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 (Extremely large effect) and a minimum of 0 (No effect). A lower score on the C-DLQI indicates increased QOL.
| score on a scale | Trifarotene |
|---|---|
| Week 12 | -1.7 ± 4.28 |
| Week 24 | -1.2 ± 5.03 |
The CompAQ questionnaire is a comprehensive measure of facial and truncal acne's impact on health-related QOL. The 20 questions consisted of 5 domains that assessed a variety of psychosocial and physical impacts of acne: Psychological/Emotional, Social (Judgement from Others), Social Interactions, Treatment Concerns, Physical Symptoms. Each question is assessed with a numeric score between 0 (Never) and 8 (All the time) with a total possible score range of 0 (No effect) -160 (greater adverse impact). The higher the score, the more quality of life is impaired.
| score on a scale | Trifarotene |
|---|---|
| Week 12 | -7.4 ± 17.39 |
| Week 24 | -0.6 ± 39.96 |
Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.
| Participants | Trifarotene |
|---|---|
| Week 12: Bothered By Treatment Side Effects: Not bothered at all | 18 |
| Week 12: Bothered By Treatment Side Effects: Bothered somewhat | 15 |
| Week 12: Bothered By Treatment Side Effects: Bothered | 0 |
| Week 12: Bothered By Treatment Side Effects: Bothered a great deal | 1 |
| Week 12: Satisfied with the time it took for treatment to work: Very satisfied | 8 |
| Week 12: Satisfied with the time it took for treatment to work: satisfied | 14 |
| Week 12: Satisfied with the time it took for treatment to work: Somewhat satisfied | 9 |
| Week 12: Satisfied with the time it took for treatment to work: Not satisfied | 3 |
| Week 12: Satisfied with effectiveness of treatment: Very satisfied | 5 |
| Week 12: Satisfied with effectiveness of treatment: satisfied | 18 |
| Week 12: Satisfied with effectiveness of treatment: Somewhat satisfied | 8 |
| Week 12: Satisfied with effectiveness of treatment: Not satisfied | 3 |
| Week 12: Feel about yourself: Very much better | 5 |
| Week 12: Feel about yourself: A lot better | 14 |
| Week 12: Feel about yourself: A little better | 13 |
| Week 12: Feel about yourself: Worse | 2 |
| Week 12: Overall-satisfied with the treatment: Very satisfied | 6 |
| Week 12: Overall-satisfied with the treatment: satisfied | 18 |
| Week 12: Overall-satisfied with the treatment: Somewhat satisfied | 7 |
| Week 12: Overall-satisfied with the treatment: Not satisfied | 3 |
| Week 12: Would you consider using this treatment again -Yes | 31 |
| Week 12: Would you consider using this treatment again - No | 3 |
| Week 12: Used moisturizing lotion: Yes | 32 |
| Week 12: Used moisturizing lotion: No | 2 |
| Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes | 23 |
| Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: No | 9 |
| Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes | 7 |
| Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No | 25 |
| Week 12: Used moisturizing lotion: moisturizer was pleasant to use: Yes | 15 |
| Week 12: Used moisturizing lotion: moisturizer was pleasant to use: No | 17 |
| Week 12: Used moisturizing lotion: None of the above: Yes | 2 |
| Week 12: Used moisturizing lotion: None of the above: No | 30 |
| Week 24/ET: Bothered By Treatment Side Effects: Not bothered at all | 22 |
| Week 24/ET: Bothered By Treatment Side Effects: Bothered somewhat | 13 |
| Week 24/ET: Bothered By Treatment Side Effects: Bothered | 4 |
| Week 24/ET: Bothered By Treatment Side Effects: Bothered a great deal | 0 |
| Week 24/ET: Satisfied with the time it took for treatment to work: Very satisfied | 9 |
| Week 24/ET: Satisfied with the time it took for treatment to work: satisfied | 20 |
| Week 24/ET: Satisfied with the time it took for treatment to work: Somewhat satisfied | 5 |
| Week 24/ET: Satisfied with the time it took for treatment to work: Not satisfied | 5 |
| Week 24/ET: Satisfied with effectiveness of treatment: Very satisfied | 11 |
| Week 24/ET: Satisfied with effectiveness of treatment: satisfied | 15 |
| Week 24/ET: Satisfied with effectiveness of treatment: Somewhat satisfied | 8 |
| Week 24/ET: Satisfied with effectiveness of treatment: Not satisfied | 5 |
| Week 24/ET: Feel about yourself: Very much better | 9 |
| Week 24/ET: Feel about yourself: A lot better | 9 |
| Week 24/ET: Feel about yourself: A little better | 19 |
| Week 24/ET: Feel about yourself: Worse | 2 |
| Week 24/ET: Overall-satisfied with the treatment: Very satisfied | 12 |
| Week 24/ET: Overall-satisfied with the treatment: satisfied | 12 |
| Week 24/ET: Overall-satisfied with the treatment: Somewhat satisfied | 11 |
| Week 24/ET: Overall-satisfied with the treatment: Not satisfied | 4 |
| Week 24/ET: Would you consider using this treatment again -Yes | 28 |
| Week 24/ET: Would you consider using this treatment again - No | 11 |
| Week 24/ET: Used moisturizing lotion: Yes | 38 |
| Week 24/ET: Used moisturizing lotion: No | 1 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes | 30 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: No | 8 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes | 7 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No | 31 |
| Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: Yes | 15 |
| Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: No | 23 |
| Week 24/ET: Used moisturizing lotion: None of the above: Yes | 2 |
| Week 24/ET: Used moisturizing lotion: None of the above: No | 36 |
Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.
| Participants | Trifarotene |
|---|---|
| Week 12: Bothered By Treatment Side Effects: Not bothered at all | 23 |
| Week 12: Bothered By Treatment Side Effects: Bothered somewhat | 9 |
| Week 12: Bothered By Treatment Side Effects: Bothered | 2 |
| Week 12: Bothered By Treatment Side Effects: Bothered a great deal | 0 |
| Week 12: Satisfied with the time it took for treatment to work: Very satisfied | 8 |
| Week 12: Satisfied with the time it took for treatment to work: satisfied | 16 |
| Week 12: Satisfied with the time it took for treatment to work: Somewhat satisfied | 8 |
| Week 12: Satisfied with the time it took for treatment to work: Not satisfied | 2 |
| Week 12: Satisfied with effectiveness of treatment: Very satisfied | 5 |
| Week 12: Satisfied with effectiveness of treatment: satisfied | 18 |
| Week 12: Satisfied with effectiveness of treatment: Somewhat satisfied | 10 |
| Week 12: Satisfied with effectiveness of treatment: Not satisfied | 1 |
| Week 12: Feel about yourself: Very much better | 6 |
| Week 12: Feel about yourself: A lot better | 14 |
| Week 12: Feel about yourself: A little better | 14 |
| Week 12: Feel about yourself: Worse | 0 |
| Week 12: Overall-satisfied with the treatment: Very satisfied | 8 |
| Week 12: Overall-satisfied with the treatment: satisfied | 13 |
| Week 12: Overall-satisfied with the treatment: Somewhat satisfied | 10 |
| Week 12: Overall-satisfied with the treatment: Not satisfied | 3 |
| Week 12: Would you consider using this treatment again -Yes | 32 |
| Week 12: Would you consider using this treatment again - No | 2 |
| Week 12: Used moisturizing lotion: Yes | 33 |
| Week 12: Used moisturizing lotion: No | 1 |
| Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes | 23 |
| Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: No | 10 |
| Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes | 8 |
| Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No | 25 |
| Week 12: Used moisturizing lotion: moisturizer was pleasant to use: Yes | 14 |
| Week 12: Used moisturizing lotion: moisturizer was pleasant to use: No | 19 |
| Week 12: Used moisturizing lotion: None of the above: Yes | 3 |
| Week 12: Used moisturizing lotion: None of the above: No | 30 |
| Week 24/ET: Bothered By Treatment Side Effects: Not bothered at all | 22 |
| Week 24/ET: Bothered By Treatment Side Effects: Bothered somewhat | 13 |
| Week 24/ET: Bothered By Treatment Side Effects: Bothered | 4 |
| Week 24/ET: Bothered By Treatment Side Effects: Bothered a great deal | 0 |
| Week 24/ET: Satisfied with the time it took for treatment to work: Very satisfied | 7 |
| Week 24/ET: Satisfied with the time it took for treatment to work: satisfied | 22 |
| Week 24/ET: Satisfied with the time it took for treatment to work: Somewhat satisfied | 5 |
| Week 24/ET: Satisfied with the time it took for treatment to work: Not satisfied | 5 |
| Week 24/ET: Satisfied with effectiveness of treatment: Very satisfied | 8 |
| Week 24/ET: Satisfied with effectiveness of treatment: satisfied | 19 |
| Week 24/ET: Satisfied with effectiveness of treatment: Somewhat satisfied | 7 |
| Week 24/ET: Satisfied with effectiveness of treatment: Not satisfied | 5 |
| Week 24/ET: Feel about yourself: Very much better | 8 |
| Week 24/ET: Feel about yourself: A lot better | 11 |
| Week 24/ET: Feel about yourself: A little better | 19 |
| Week 24/ET: Feel about yourself: Worse | 1 |
| Week 24/ET: Overall-satisfied with the treatment: Very satisfied | 10 |
| Week 24/ET: Overall-satisfied with the treatment: satisfied | 17 |
| Week 24/ET: Overall-satisfied with the treatment: Somewhat satisfied | 9 |
| Week 24/ET: Overall-satisfied with the treatment: Not satisfied | 3 |
| Week 24/ET: Would you consider using this treatment again -Yes | 28 |
| Week 24/ET: Would you consider using this treatment again - No | 11 |
| Week 24/ET: Used moisturizing lotion: Yes | 37 |
| Week 24/ET: Used moisturizing lotion: No | 2 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes | 30 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: No | 7 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes | 8 |
| Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No | 29 |
| Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: Yes | 13 |
| Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: No | 24 |
| Week 24/ET: Used moisturizing lotion: None of the above: Yes | 2 |
| Week 24/ET: Used moisturizing lotion: None of the above: No | 35 |
EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United States (US) algorithm, with scores ranging from -0.109 (extreme problems) to 1 (no problems). A higher score indicates better health state.
| score on a scale | Trifarotene |
|---|---|
| Week 12 | -0.0140 ± 0.09626 |
| Week 24 | 0.0135 ± 0.08394 |
The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 (the worst imaginable health) to 100 (the best imaginable health), with higher scores indicating higher health utility.
| score on a scale | Trifarotene |
|---|---|
| Week 12 | 1.0 ± 8.96 |
| Week 24 | 3.7 ± 7.96 |
IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24.
| percentage of participants | Trifarotene |
|---|---|
| Week 12 | 6.4 (1.3 to 17.5) |
| Week 24 | 19.1 (9.1 to 33.3) |
The Physician's Global Assessment (PGA) was an instrument to evaluate the truncal acne severity in the shoulders, upper back and upper anterior chest areas. PGA was recorded from components collected on the CRF using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an PGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24. All missing values were imputed by LOCF.
| percentage of participants | Trifarotene |
|---|---|
| Week 12 | 14.9 (6.2 to 28.3) |
| Week 24 | 6.4 (1.3 to 17.5) |
Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
| percent change | Trifarotene |
|---|---|
| Inflammatory Lesion: Week 12 | -35.81 ± 41.124 |
| Inflammatory Lesion: Week 24 | -38.59 ± 42.643 |
| Non-Inflammatory Lesion: Week 12 | -23.17 ± 45.506 |
| Non-Inflammatory Lesion: Week 24 | -35.16 ± 46.946 |
Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.
| percent change | Trifarotene |
|---|---|
| Inflammatory Lesion: Week 12 | -39.97 ± 32.564 |
| Inflammatory Lesion: Week 24 | -41.36 ± 39.131 |
| Non-Inflammatory Lesion: Week 12 | -35.24 ± 39.337 |
| Non-Inflammatory Lesion: Week 24 | -44.20 ± 37.650 |
Collected over From start of the study drug administration up to end of the study (Week 24).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trifarotene | 0/46 (0%) | 0/46 (0%) | 9/46 (19.6%) |
| Event | Trifarotene |
|---|---|
| Application site painGeneral disorders | 5/46 |
| Application site dermatitisGeneral disorders | 3/46 |
| SunburnInjury, poisoning and procedural complications | 3/46 |
Analysis was performed on Intent to treat (ITT) population that included all enrolled participants.
| Age, Continuous(years) | Trifarotene |
|---|---|
| Mean | 15.6 ± 3.00 |
| Sex: Female, Male(Participants) | Trifarotene |
|---|---|
| Female | 13 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | Trifarotene |
|---|---|
| Hispanic or Latino | 10 |
| Not Hispanic or Latino | 37 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Trifarotene |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 42 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Dermatology Life Quality Index (DLQI) Score at Baseline(score on a scale) | Trifarotene |
|---|---|
| Mean | 2.8 ± 3.00 |
| C-DLQI (Children's Dermatology Life Quality Index) Score at Baseline(score on a scale) | Trifarotene |
|---|---|
| Mean | 3.2 ± 4.17 |
| Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne at Baseline(score on a scale) | Trifarotene |
|---|---|
| Mean | 37.8 ± 17.69 |
| EuroQoL 5-Dimension (EQ-5D-5L) Index Score at Baseline(score on a scale) | Trifarotene |
|---|---|
| Mean | 0.9416 ± 0.07334 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Dec 2019, 8 months.
Results were first posted in Dec 2021, 1 year 11 months after primary completion.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 8 months is below that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene